Recent Updates
Recently added Catalysts
ARWR Positive Sentiment

Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress

Monday, August 24, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Arrowhead Pharmaceuticals announced it will present new clinical data at the European Society of Cardiology Congress in Munich. The presentation will focus on the SHASTA-3 and SHASTA-4 pivotal trial results for Plozasiran in patients with severe hypertriglyceridemia. This event is scheduled for August 30, 2026.

Market Sentiment Analysis

POSITIVE FACTORS

  • Arrowhead Pharmaceuticals is presenting new clinical data.
  • The presentation will occur at a prestigious conference.
  • The data pertains to a pivotal trial for a significant health issue.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+381%
120-day peak, hindsight
Typical move
2.1%
average across 2 past catalysts
Cash runway
~27 mo
Minimal dilution risk
Lead asset
Plozasiran
Phase 3 · Hypertriglyceridemia

Full Press Release Details

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will present important new data at the European Society of Cardiology Congress (ESC) in Munich, Germany. ESC 2026 Presentation Details Date & Time: Sunday, August 30, 2026, 17:30 CEST Session Title: HOT LINE 9 Late-breaking Science Session Location: Munich Auditorium-Hall B3 Title: Plozasiran in patients with severe hypertriglyceridemia: the SHASTA-3 and SHASTA-4 pivotal trial 12-month

Frequently Asked Questions

What is the focus of Arrowhead's presentation?

The presentation will focus on Plozasiran in patients with severe hypertriglyceridemia.

When will Arrowhead present at the ESC Congress?

Arrowhead will present on August 30, 2026, at 17:30 CEST.

Where is the ESC Congress being held?

The ESC Congress is being held in Munich, Germany.

What trials will be discussed during the presentation?

The SHASTA-3 and SHASTA-4 pivotal trials will be discussed.

ShareAdd on Google
Tags: ARWR Viatris Investor Conferences Healthcare Arrowhead Pharmaceuticals ESC Congress Plozasiran hypertriglyceridemia clinical data
Last updated: Aug 24, 2026

Biotech snapshot

Cash runway
$1602M liquidity · $59M/mo burn
~27 mo
Minimal dilution risk
Lead asset
PlozasiranPhase 3
Hypertriglyceridemia →

Catalyst track record

+381%
best trade around ARWR's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for ARWR.

See every catalyst's timing & PoA →